These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
235 related articles for article (PubMed ID: 22561413)
1. LPS challenge in healthy subjects: an investigation of neutrophil chemotaxis mechanisms involving CXCR1 and CXCR2. Aul R; Patel S; Summerhill S; Kilty I; Plumb J; Singh D Int Immunopharmacol; 2012 Jul; 13(3):225-31. PubMed ID: 22561413 [TBL] [Abstract][Full Text] [Related]
2. Combined anti CXC receptors 1 and 2 therapy is a promising anti-inflammatory treatment for respiratory diseases by reducing neutrophil migration and activation. Planagumà A; Domènech T; Pont M; Calama E; García-González V; López R; Aulí M; López M; Fonquerna S; Ramos I; de Alba J; Nueda A; Prats N; Segarra V; Miralpeix M; Lehner MD Pulm Pharmacol Ther; 2015 Oct; 34():37-45. PubMed ID: 26271598 [TBL] [Abstract][Full Text] [Related]
3. Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist. Gonsiorek W; Fan X; Hesk D; Fossetta J; Qiu H; Jakway J; Billah M; Dwyer M; Chao J; Deno G; Taveras A; Lundell DJ; Hipkin RW J Pharmacol Exp Ther; 2007 Aug; 322(2):477-85. PubMed ID: 17496166 [TBL] [Abstract][Full Text] [Related]
4. Neutrophil chemotaxis caused by chronic obstructive pulmonary disease alveolar macrophages: the role of CXCL8 and the receptors CXCR1/CXCR2. Kaur M; Singh D J Pharmacol Exp Ther; 2013 Oct; 347(1):173-80. PubMed ID: 23912333 [TBL] [Abstract][Full Text] [Related]
5. SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects. Holz O; Khalilieh S; Ludwig-Sengpiel A; Watz H; Stryszak P; Soni P; Tsai M; Sadeh J; Magnussen H Eur Respir J; 2010 Mar; 35(3):564-70. PubMed ID: 19643947 [TBL] [Abstract][Full Text] [Related]
6. A novel, orally active CXCR1/2 receptor antagonist, Sch527123, inhibits neutrophil recruitment, mucus production, and goblet cell hyperplasia in animal models of pulmonary inflammation. Chapman RW; Minnicozzi M; Celly CS; Phillips JE; Kung TT; Hipkin RW; Fan X; Rindgen D; Deno G; Bond R; Gonsiorek W; Billah MM; Fine JS; Hey JA J Pharmacol Exp Ther; 2007 Aug; 322(2):486-93. PubMed ID: 17496165 [TBL] [Abstract][Full Text] [Related]
7. Downmodulation of CXCL8/IL-8 receptors on neutrophils after recruitment in the airways. Pignatti P; Moscato G; Casarini S; Delmastro M; Poppa M; Brunetti G; Pisati P; Balbi B J Allergy Clin Immunol; 2005 Jan; 115(1):88-94. PubMed ID: 15637552 [TBL] [Abstract][Full Text] [Related]
8. Rabbit neutrophil chemotactic protein (NCP) activates both CXCR1 and CXCR2 and is the functional homologue for human CXCL6. Catusse J; Struyf S; Wuyts A; Weyler M; Loos T; Gijsbers K; Gouwy M; Proost P; Van Damme J Biochem Pharmacol; 2004 Nov; 68(10):1947-55. PubMed ID: 15476666 [TBL] [Abstract][Full Text] [Related]
9. The effects of a CXCR1/CXCR2 antagonist on neutrophil migration in mild atopic asthmatic subjects. Todd CM; Salter BM; Murphy DM; Watson RM; Howie KJ; Milot J; Sadeh J; Boulet LP; O'Byrne PM; Gauvreau GM Pulm Pharmacol Ther; 2016 Dec; 41():34-39. PubMed ID: 27640067 [TBL] [Abstract][Full Text] [Related]
10. The combined CXCR1/CXCR2 antagonist CXCL8(3-74)K11R/G31P blocks neutrophil infiltration, pyrexia, and pulmonary vascular pathology in endotoxemic animals. Gordon JR; Li F; Zhang X; Wang W; Zhao X; Nayyar A J Leukoc Biol; 2005 Dec; 78(6):1265-72. PubMed ID: 16204619 [TBL] [Abstract][Full Text] [Related]
11. CXCR2 antagonists block the N-Ac-PGP-induced neutrophil influx in the airways of mice, but not the production of the chemokine CXCL1. Braber S; Overbeek SA; Koelink PJ; Henricks PA; Zaman GJ; Garssen J; Kraneveld AD; Folkerts G Eur J Pharmacol; 2011 Oct; 668(3):443-9. PubMed ID: 21458445 [TBL] [Abstract][Full Text] [Related]
12. SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans. Lazaar AL; Sweeney LE; MacDonald AJ; Alexis NE; Chen C; Tal-Singer R Br J Clin Pharmacol; 2011 Aug; 72(2):282-93. PubMed ID: 21426372 [TBL] [Abstract][Full Text] [Related]
13. Effect of formoterol and budesonide on chemokine release, chemokine receptor expression and chemotaxis in human neutrophils. Strandberg K; Blidberg K; Sahlander K; Palmberg L; Larsson K Pulm Pharmacol Ther; 2010 Aug; 23(4):316-23. PubMed ID: 20307681 [TBL] [Abstract][Full Text] [Related]
14. CXCL8((3-73))K11R/G31P antagonizes ligand binding to the neutrophil CXCR1 and CXCR2 receptors and cellular responses to CXCL8/IL-8. Li F; Zhang X; Gordon JR Biochem Biophys Res Commun; 2002 May; 293(3):939-44. PubMed ID: 12051749 [TBL] [Abstract][Full Text] [Related]
15. The collagen-breakdown product N-acetyl-Proline-Glycine-Proline (N-alpha-PGP) does not interact directly with human CXCR1 and CXCR2. de Kruijf P; Lim HD; Overbeek SA; Zaman GJ; Kraneveld AD; Folkerts G; Leurs R; Smit MJ Eur J Pharmacol; 2010 Sep; 643(1):29-33. PubMed ID: 20599927 [TBL] [Abstract][Full Text] [Related]
16. The CXCL8/IL-8 chemokine family and its receptors in inflammatory diseases. Russo RC; Garcia CC; Teixeira MM; Amaral FA Expert Rev Clin Immunol; 2014 May; 10(5):593-619. PubMed ID: 24678812 [TBL] [Abstract][Full Text] [Related]
17. Il-8((3-73))K11R is a high affinity agonist of the neutrophil CXCR1 and CXCR2. Li F; Gordon JR Biochem Biophys Res Commun; 2001 Aug; 286(3):595-600. PubMed ID: 11511101 [TBL] [Abstract][Full Text] [Related]
18. Towards in situ tissue repair: human mesenchymal stem cells express chemokine receptors CXCR1, CXCR2 and CCR2, and migrate upon stimulation with CXCL8 but not CCL2. Ringe J; Strassburg S; Neumann K; Endres M; Notter M; Burmester GR; Kaps C; Sittinger M J Cell Biochem; 2007 May; 101(1):135-46. PubMed ID: 17295203 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of potent and selective small-molecule antagonists for the CXCR2 chemokine receptor. Widdowson KL; Elliott JD; Veber DF; Nie H; Rutledge MC; McCleland BW; Xiang JN; Jurewicz AJ; Hertzberg RP; Foley JJ; Griswold DE; Martin L; Lee JM; White JR; Sarau HM J Med Chem; 2004 Mar; 47(6):1319-21. PubMed ID: 14998320 [TBL] [Abstract][Full Text] [Related]
20. Discovery of 2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5- methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): a potent, orally bioavailable CXCR2/CXCR1 receptor antagonist. Dwyer MP; Yu Y; Chao J; Aki C; Chao J; Biju P; Girijavallabhan V; Rindgen D; Bond R; Mayer-Ezel R; Jakway J; Hipkin RW; Fossetta J; Gonsiorek W; Bian H; Fan X; Terminelli C; Fine J; Lundell D; Merritt JR; Rokosz LL; Kaiser B; Li G; Wang W; Stauffer T; Ozgur L; Baldwin J; Taveras AG J Med Chem; 2006 Dec; 49(26):7603-6. PubMed ID: 17181143 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]